Visit number | Screening period | Follow-up period | ||
---|---|---|---|---|
1 | 2 | 3 | 4 | |
Research arrangement | Screening | 90 ± 14 days | 180 ± 30 days | 365 ± 30 days |
Informed consent | √ | |||
Selection criteria | √ | |||
Baseline information | √ | |||
History of disease and history of medicine taking | √ | |||
Medicine taking | √ | √ | √ | |
Symptoms and physical examination | √ | √ | √ | √ |
Electrocardiogram | √ | |||
Routine blood test | √ | |||
Blood sugar | √ | |||
Blood lipid | √ | |||
Homocysteine | √ | |||
Head CT/MRI | √ | √ | √ | √ |
CTA/MRA/DSA | √ | √ | ||
Vascular ultrasound | √ | √ | ||
mRS score | √ | √ | √ | √ |
HAMA score | √ | √ | √ | √ |
End point evaluation | √ | √ | √ | |
Adverse event evaluation | √ | √ | √ |